

Rebecca Weiser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9088165/publications.pdf>

Version: 2024-02-01

11
papers

362
citations

1163117

8
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

577
citing authors

#	ARTICLE	IF	CITATIONS
1	Beware biofilm! Dry biofilms containing bacterial pathogens on multiple healthcare surfaces; a multi-centre study. <i>Journal of Hospital Infection</i> , 2018, 100, e47-e56.	2.9	99
2	Discovery and Biosynthesis of Gladiolin: A <i>Burkholderia gladioli</i> Antibiotic with Promising Activity against <i>Mycobacterium tuberculosis</i> . <i>Journal of the American Chemical Society</i> , 2017, 139, 7974-7981.	13.7	73
3	Phenotypic characterization of an international <i>Pseudomonas aeruginosa</i> reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains. <i>Microbiology (United Kingdom)</i> 157, 1071-1081.	1.0	10
4	Not all <i>Pseudomonas aeruginosa</i> are equal: strains from industrial sources possess uniquely large multireplicon genomes. <i>Microbial Genomics</i> , 2019, 5, .	2.0	26
5	Evaluation of five selective media for the detection of <i>Pseudomonas aeruginosa</i> using a strain panel from clinical, environmental and industrial sources. <i>Journal of Microbiological Methods</i> , 2014, 99, 8-14.	1.6	22
6	Antibiotic Therapy and the Gut Microbiome: Investigating the Effect of Delivery Route on Gut Pathogens. <i>ACS Infectious Diseases</i> , 2021, 7, 1283-1296.	3.8	22
7	Understanding the challenges of non-food industrial product contamination. <i>FEMS Microbiology Letters</i> , 2019, 366, .	1.8	19
8	Phenotypic and Genotypic Adaptations in <i>Pseudomonas aeruginosa</i> Biofilms following Long-Term Exposure to an Alginate Oligomer Therapy. <i>MSphere</i> , 2021, 6, .	2.9	10
9	A Novel Inducible Prophage from <i>Burkholderia vietnamiensis</i> G4 Is Widely Distributed across the Species and Has Lytic Activity against Pathogenic <i>Burkholderia</i> . <i>Viruses</i> , 2020, 12, 601.	3.3	8
10	Evaluating the alginate oligosaccharide (OligoG) as a therapy for <i>Burkholderia cepacia</i> complex cystic fibrosis lung infection. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 821-829.	0.7	8
11	Implementation of microbiota analysis in clinical trials for cystic fibrosis lung infection: Experience from the OligoG phase 2b clinical trials. <i>Journal of Microbiological Methods</i> , 2021, 181, 106133.	1.6	4